Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched sequencing in Chinese patients with advanced non-small cell lung cancer
B Jiang, F Liu, L Yang, W Zhang… - Journal of …, 2011 - journals.sagepub.com
Epidermal growth factor receptor gene (EGFR) mutations are among the best predictive
markers of the efficacy of EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment. Mutations in …
markers of the efficacy of EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment. Mutations in …
Primary tumor resection for stage IV non-small-cell lung cancer without progression after first-line epidermal growth factor receptor-tyrosine kinase inhibitor treatment …
Background In studies of stage IV epidermal growth factor receptor (EGFR)-mutant nonsmall-
cell lung cancer (NSCLC),< 10% of patients underwent surgery; thus, the effect of surgery in …
cell lung cancer (NSCLC),< 10% of patients underwent surgery; thus, the effect of surgery in …
A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
T Kobayashi, T Koizumi, T Agatsuma, M Yasuo… - Cancer chemotherapy …, 2012 - Springer
Purpose There is as yet no optimal treatment regimen for patients with epidermal growth
factor receptor (EGFR) gene wild-type non-small-cell lung cancer (NSCLC) that has …
factor receptor (EGFR) gene wild-type non-small-cell lung cancer (NSCLC) that has …
DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib
S Zhu, A Belkhiri, W El-Rifai - Gastroenterology, 2011 - Elsevier
BACKGROUND & AIMS: Dopamine and adenosine 3′, 5′-cyclic monophosphate–
regulated phosphoprotein, Mr 32000 (DARPP-32), is overexpressed during gastric …
regulated phosphoprotein, Mr 32000 (DARPP-32), is overexpressed during gastric …
Improving nanochemoimmunotherapy efficacy by boosting “eat-me” signaling and downregulating “don't-eat-me” signaling with Ganoderma lucidum polysaccharide …
G Pang, S Wei, J Zhao, FJ Wang - Journal of Materials Chemistry B, 2023 - pubs.rsc.org
To address the challenges posed by low immunogenicity and immune checkpoints during
cancer treatment, we propose an alternative strategy that combines immunogenic cell death …
cancer treatment, we propose an alternative strategy that combines immunogenic cell death …
A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK fusion gene
X Chen, J Zhang, Q Hu, X Li, C Zhou - Lung Cancer, 2013 - Elsevier
We report a man with advanced adenocarcinoma who harboring exon 19 (E746-A750del)
epidermal growth factor receptor (EGFR) deletion and echinoderm microtubule-associated …
epidermal growth factor receptor (EGFR) deletion and echinoderm microtubule-associated …
Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy …
Y Wang, RQ Li, YQ Ai, J Zhang, PZ Zhao, YF Li… - Clinical and …, 2015 - Springer
Objective To determine whether the specific genotype of exon 19 deletion has a better
survival outcome than that of exon 21 substitution in advanced lung adenocarcinoma with …
survival outcome than that of exon 21 substitution in advanced lung adenocarcinoma with …
Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis
W Zhang, Y Wei, D Yu, J Xu, J Peng - BMC cancer, 2018 - Springer
Background The first-generation epidermal growth factor receptor tyrosine kinase inhibitors
gefitinib and erlotinib have both been proven effective for treating advanced non–small cell …
gefitinib and erlotinib have both been proven effective for treating advanced non–small cell …
Genomic profiling of multiple sequentially acquired tumor metastatic sites from an “exceptional responder” lung adenocarcinoma patient reveals extensive genomic …
R Biswas, S Gao, CM Cultraro… - Molecular …, 2016 - molecularcasestudies.cshlp.org
We used next-generation sequencing to identify somatic alterations in multiple metastatic
sites from an “exceptional responder” lung adenocarcinoma patient during his 7-yr course of …
sites from an “exceptional responder” lung adenocarcinoma patient during his 7-yr course of …